eli lilly glp-1 advantage decreasing Lilly's weight-loss drug reduces sleep apnea severity in late-stage trials Lilly's GLP-1 portfolio gains ground

Ask whether they do baseline bloodwork, monitor metabolic changes, and have a plan for what happens when you reach your goal weight

Reduced cardiovascular risk Studies suggest potential benefits for heart health

In commercial plans and employer groups, adoption is accelerating: a 2025 Health Affairs/KFF survey found that 43% of firms with 5,000+ employees now cover GLP-1s for weight loss, up from 28% in 2024 ( [26] ), and 57% of employers overall cover GLP-1s for weight loss according to WTW survey data ( [27] )

Surprisingly, Hims announced it was in discussions with Novo to make Wegovy available through Hims online platform at its third quarter earnings call in November 2025

GLP-1 drugs like Ozempic, Wegovy, and Zepbound have become commonplace in America

PMCID: PMC4159612